Pall Corp.'s decision to sell some of its blood and transfusion assets, for $550 million, marks a shift in strategy for the global filtration maker during its first year under a new chief ...

the risk of transmission of vCJD and other forms of human prion disease through blood transfusion." The Pall Leukotrap® Affinity Prion Reduction Filter System reduces both leukocytes and ...

Pall's leukoreduction filters are the global standard of care for transfusion medicine. Roberto Perez, President, Pall Life Sciences added, “Our goal is to help blood centers and hospitals ...

The Pall LeukotrapR Affinity Prion Reduction Filter system is the only Council of Europe (CE) marked technology shown to remove prions from red blood cells, the most commonly transfused blood ...

Pall is selling certain assets of its blood collection, filtration, and processing product lines to Haemonetics for roughly $550 million. The transaction includes related systems as well as ...

Filtration equipment manufacturer Pall Corp. has agreed to sell certain operations and equipment used in blood transfusions to health care company Haemonetics Corp. for about $550 million.

Haemonetics Corporation,a global healthcare company, has entered into a definitive agreement to acquire the business assets of the blood collection, filtration and processing product lines of Pall ...

Pall Corp., a Port Washington, N.Y., maker of filtration equipment, has agreed to sell certain operations and equipment used in blood transfusions to the Braintree health care company Haemonetics ...

Pall Corporation PLL announced Sunday it has entered into an agreement to sell certain assets of its blood collection, filtration and processing product lines to Haemonetics Corporation HAE for ...